← Back to Clinical Trials
Recruiting NCT05916430

NCT05916430 Screening for Autism in 9-Month-Olds by Measuring Social Visual Engagement

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05916430
Status Recruiting
Phase
Sponsor Emory University
Condition Autism
Study Type OBSERVATIONAL
Enrollment 2,120 participants
Start Date 2023-02-02
Primary Completion 2027-12

Eligibility & Interventions

Sex All sexes
Min Age 8 Months
Max Age 10 Months
Study Type OBSERVATIONAL
Interventions
EarliPoint Investigational Device

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 2,120 participants in total. It began in 2023-02-02 with a primary completion date of 2027-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this project is to measure the clinical utility of an objective and quantitative eye-tracking assay collected on a standalone, mobile investigational device to accurately screen 9-month-old infants for autism spectrum disorder and other actionable delays.

Eligibility Criteria

Inclusion Criteria: * Infants between the chronological ages of 8-10 months * Infants must be generally healthy with no acute illnesses likely to prevent successful or valid data collection (e.g., current vomiting, high fever, conjunctivitis affecting vision) * Participants' parents/caregivers must be able to understand and voluntarily provide written informed consent. Exclusion Criteria: \- Children will be excluded if they have signs of acute illness likely to prevent successful or valid data collection (e.g., conjunctivitis affecting vision, current vomiting, or high fever).

Contact & Investigator

Central Contact

FirstFocus Study

✉ FirstFocus@emory.edu

📞 404-785-4529

Principal Investigator

Warren R Jones, PhD

PRINCIPAL INVESTIGATOR

Emory University

Frequently Asked Questions

Who can join the NCT05916430 clinical trial?

This trial is open to participants of all sexes, aged 8 Months or older, up to 10 Months, studying Autism. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05916430 currently recruiting?

Yes, NCT05916430 is actively recruiting participants. Contact the research team at FirstFocus@emory.edu for enrollment information.

Where is the NCT05916430 trial being conducted?

This trial is being conducted at Atlanta, United States, Atlanta, United States.

Who is sponsoring the NCT05916430 clinical trial?

NCT05916430 is sponsored by Emory University. The principal investigator is Warren R Jones, PhD at Emory University. The trial plans to enroll 2,120 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology